Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
France to build new nuclear aircraft carrier, Macron says - 2Smoking rate among US adults drops to record low as vape use rises, CDC report finds
- 3The Universe of Impeccable Pearls: A Manual for Valuable Gems
- 4Extreme Manual for Purchasing Your Next Truck
- 5A Texas GOP congressman is retiring. Trump just endorsed his identical twin to replace him.
- Rocket Lab launches mystery satellite for 'confidential commercial customer' (video)
- I watched more than 500 new movies this year. These are the 25 best ones.
- Volunteers aiding humpback whale stranded in Baltic get death threats
- Hamas demanded displaced Gazans pay rent on beach tents amid torrential downpour, IDF reveals
- Figuring out the Business venture Code: The Response to Building an Effective Startup
- NATO official says members often aren't buying weapons together, and it's a mistake
- Where America’s CO2 emissions come from – what you need to know, in charts
- From candy cane fishing to ornament switcharoo, here are some of the best games you can play with your loved ones this holiday season
- Arrow Exploration brings new Colombian oil well on stream ahead of schedule and under budget
